) is scheduled to report first quarter 2014 results before the
opening bell on Apr 25. Last quarter, AbbVie had posted an
earnings surprise of -1.20%. Let's see how things are shaping up
for this announcement.
Factors at Play
Although Humira will continue to boost revenues, AbbVie's
top-line will remain under pressure with the loss of exclusivity
of TriCor, TriLipix and Niaspan. Unfavorable currency movement is
also expected to impact the top line. We also remain concerned
about AbbVie's dependence on Humira due to intense competition in
Meanwhile, other products like Synthroid, Creon, Zemplar and
Duodopa should continue to perform well and partially offset the
impact of genericization.
Our proven model does not conclusively show that AbbVie is likely
to beat earnings this quarter. That is because a stock needs to
have both a positive
(Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for
this to happen. That is not the case here as you will see below.
The Earnings ESP for AbbVie is -1.47% since the Most Accurate
estimate is $0.67 while the Zacks Consensus Estimate is $0.68.
Zacks #3 Rank (Hold):
AbbVie's Zacks Rank #3 (Hold) has little effect on the predictive
power of ESP because the Zacks Rank #3 when combined with a
negative ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies you may want to consider as our
model shows that they have the right combination of elements,
i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or
) has an Earnings ESP of +3.34% and holds a Zacks Rank #2 (Buy).
Actavis will report first quarter earnings on Apr 30.
Teva Pharmaceutical Industries Ltd.
) has an Earnings ESP of +0.00% and holds a Zacks Rank #2. Teva
will report first quarter earnings on May 1.
Forest Laboratories Inc.
) has an Earnings ESP of +4.55% and holds a Zacks Rank #3. Forest
Labs will report first quarter earnings on Apr 29.
ABBVIE INC (ABBV): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
FOREST LABS A (FRX): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.